$GCTK

Glucotrack, Inc.

Glucotrack is a medical device company developing an implantable continuous blood glucose monitor for people with Type 1 diabetes and people with Type 2 diabetes who use insulin or are at risk for hypoglycemia. Its Glucotrack CBGM is designed for long-term implantation, with a sensor connected to a lead placed directly into a blood vessel to measure glucose continuously. The company is also evaluating continuous glucose sensing in the epidural space for people undergoing spinal cord stimulation therapy. Glucotrack makes no sales from a commercial product described here; its CBGM remains under development and has not been approved for commercial sale. The company previously developed Glucotrack, a non-invasive device that measured glucose through an earlobe sensor, but withdrew its CE Mark and no longer pursues that product. Glucotrack is headquartered in Rutherford, New Jersey.

No enriched coverage for $GCTK in the last 7 days.

No SEC Form 4 filings for $GCTK in the last 30 days.

See all $GCTK insider activity →
High

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

GCTK sentiment & insider activity

Recent GCTK coverage spans corporate actions, mergers & acquisitions and market movers.

What's driving GCTK

  • The merger creates a larger combined entity but introduces a significant day‑one loss and multiple reverse splits, likely pressuring the stock lower in the short term.

    SEC EDGAR 8-K · Oct 28, 2026

  • The Qare launch provides a narrative boost but the company remains cash‑burning and volatile.

    stockstotrade.com · Oct 28, 2026

  • The convertible note issuance may dilute existing shareholders and add debt, likely pressuring the stock lower.

    tradingview.com · Oct 22, 2026

  • The reverse split reduces share count by half, aiming to lift the share price above $1.00, which may attract institutional investors and stabilize the stock.

    SEC EDGAR 8-K · Oct 22, 2026

  • The split reduces share count, potentially boosting share price and liquidity, but may cause short-term volatility.

    stocktitan.net · Oct 22, 2026

AlphAI scores every news story that mentions GCTK with an AI model for sentiment and relevance, and aggregates insider trades from Glucotrack, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GCTK

Score
$GCTKHighM&A· acquirer · completed

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKHighListing notice· deficiency

Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Reverse Stock Split 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 RUTHERFORD, N.J., and LA JOLLA, C.A., October 22, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a

$GCTKMedOffering· 406.2K · proposed

Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per shar

Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications

Glucotrack's subsidiary Lōkahi Therapeutics launched Qare, a health platform for comparing medication experiences, starting with GLP-1 drugs. The app matches users by profile and medication, generating real-world data. Lōkahi aims to expand Qare to other therapeutic categories and believes it may offer long-term value to patients and manufacturers.

Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on July 14, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement as supplemented by a joinder dated August 4, 2026 (the “Purchase Agreement”), with certain investors (th

$GCTKLowOffering· $3.1M · priced

Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.: Sept. 24, 2026—(BUSINESS WIRE)—Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169

Related tickers